Massive study aims to uncover hidden triggers of blood cancers
NCT ID NCT01728402
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times
Summary
This study is collecting blood, bone marrow, and tissue samples from 5,000 people with blood cancers like leukemia and lymphoma. Researchers will analyze the samples to find genetic abnormalities that cause cancer cells to grow. The goal is to understand why these cancers develop so that future treatments can be more effective and less harsh.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this research could reveal the root causes of blood cancers, pointing toward more targeted and effective treatments.
- What could go wrong
- This is an observational study, not a treatment trial. It may take years to translate findings into actual therapies, and many discoveries do not lead to new drugs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 5,000 people
The number the study aims to enrol. It can still change while the study runs.
- Start date
-
Sep 2008
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients of any age with a diagnosis or suspected diagnosis of a blood or bone marrow cancer may be a part of this study. The provider who will perform the blood draw, bone marrow aspirate, or biopsy as part of the patient's routine care will identify possible participants from their clinic schedule or patient list, give them information about what would be involved in participating in the study including possible risks, and ask if they are interested in participating.
- Ages
-
1 year and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Suspected or confirmed diagnosis of AL, LPD, MDS, or MPD * Male or female of all ages * Willing and able to sign informed consent * Willing guardian consent for participants under 18 years of age Exclusion Criteria: * No suspected or confirmed diagnosis of acute leukemias (AL), lymphoproliferative disorders (LPD), myelodysplastic syndromes (MDS), or myeloproliferative diseases (MPD)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute leukemia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can adding venetoclax make donor stem cell transplants safer for High-Risk blood cancers?
- Tweaking donor cells may shield older transplant patients from a dangerous complication
- Can starting anemia drug sooner keep MDS patients off transfusions?
- Blood cancer registry tracks thousands to map disease course
- New drug combination targets Hard-to-Treat blood cancers
- Can a calming drug make cord blood transplants safer?